-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – US Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – 5EU Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Japan Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – China Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Global Polyethylene Industry Outlook to 2023 – Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants
Global polyethylene capacity is expected to experience considerable growth over the next five years from around 110 mtpa in 2018 to more than 150 mtpa by 2023. More than 159 planned and announced polyethylene plants are expected to come online, primarily in Asia and the Middle East over the next five years. Badlands NGLS LLC, Oil and Natural Gas Corp Ltd and Royal Dutch Shell Plc are the top three companies in terms of planned and announced capacity additions during...
-
Sector Analysis
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Retailing in Belgium– Market Summary & Forecasts; Comprehensive overview of the market, consumer, and competitive context, with retail sales value and forecasts to 2020
Belgium’s retail sector is currently affected by various macro-economic factors- low inflation and low GDP growth, have ruled the country. However, the economic recovery along with the increase of exports and investments in Belgium are picking up which are sending positive signs of retail growth. On the other hand, high internet penetration, very high mobile penetration, and rising Smartphone sales are expected to fuel the online retail channel. Overall, we expect an optimistic retail environment in the next five years.
-
Sector Analysis
Russia Anesthesia and Respiratory Devices Market Outlook to 2025 – Anesthesia Devices, Airway Management, Respiratory Devices and Diagnostic and Measurement Devices.
“What is covered in the report about the “Russia Anesthesia and Respiratory Devices Market”? GlobalData’s “Russia Anesthesia and Respiratory Devices Market Outlook to 2025” report is a comprehensive databook report, covering key market data on the Russia Anesthesia and Respiratory Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Airway Management, Anesthesia Devices, Diagnostic and Measurement Devices and Respiratory Devices. The Russia Anesthesia and Respiratory Devices Market report provides key information...
-
Sector Analysis
Global Polyethylene Industry Outlook to 2024 – Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants
Global polyethylene capacity is expected to experience considerable growth over the next five years from 114.43 mtpa in 2019 to 173.55 mtpa by 2024. Around 154 planned and announced polyethylene projects are expected to come online predominantly in Asia, followed by the Middle East over the upcoming years. Among countries, the US is expected to lead polyethylene capacity additions by 2024, followed by China and Russia.
-
Sector Analysis
Immuno-Oncology – Focus on Developments and Opportunities in Immune Checkpoint Modulators
Immuno-oncology (IO) is the study and development of specialized treatments or immunotherapies for cancer to overcome the immune evasion mechanisms and to stimulate and enhance the immune system’s combat against cancer cells. This report focuses on immune checkpoint modulators and provides an overview of the current and emerging key products and players within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), main unmet needs; R&D challenges, strategies and opportunities; and clinical development trends. The report also includes competitive...